发明授权
US09527841B2 Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
有权
取代的吡啶并[2,3-b]吡嗪作为磷酸二酯酶2A抑制剂
![Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors](/docs/US/2016-12-27/US09527841B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
- 专利标题（中）： 取代的吡啶并[2,3-b]吡嗪作为磷酸二酯酶2A抑制剂
-
申请号： US14414020申请日： 2013-07-12
-
公开(公告)号： US09527841B2公开(公告)日： 2016-12-27
- 发明人: Shinji Nakamura , Satoshi Mikami , Kawasaki Masanori , Izumi Nomura , Tomoko Ashizawa , Takahiko Taniguchi
- 申请人： Takeda Pharmaceutical Company Limited
- 申请人地址： JP Osaka
- 专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人地址： JP Osaka
- 代理机构： Hamre, Schumann, Mueller & Larson, P.C.
- 优先权： JP2012-158096 20120713
- 国际申请： PCT/JP2013/069189 WO 20130712
- 国际公布： WO2014/010732 WO 20140116
- 主分类号： C07D241/38
- IPC分类号： C07D241/38 ; C07D471/04 ; C07D235/16
![Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors](/abs-image/US/2016/12/27/US09527841B2/abs.jpg.150x150.jpg)
摘要：
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
公开/授权文献
- US20150158863A1 HETEROCYCLIC COMPOUND 公开/授权日：2015-06-11
信息查询
